Thus, to treat DME, clinicians might be better to combine anti-VEGF injections with other therapies (direct photocoagulation of microaneurysms or sub-Tenon’s triamcinolone acetonide injection and vitrectomy) as well as systemic improvement of diabetes control with the inclusion of sodium–glucose cotransporter 2 inhibitors [26] and lipid metabolism. The gene discussed is VEGFA; the disease is diabetes mellitus.